Intervention
Aromatase Inhibitors
ClinicalTrials.gov intervention label
Clinical trials
17 shownFovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerNCT07616427 · 2026-05-20
RECRUITINGEfficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerNCT07616453 · 2026-05-06
RECRUITINGBRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNCT07596212 · 2026-09-01
NOT_YET_RECRUITINGImpact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast CancerNCT04352777 · 2020-09-14
COMPLETEDNiraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)NCT04240106 · 2020-06-15
COMPLETEDStudy Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)NCT04227327 · 2020-01-07
TERMINATEDPyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerNCT04088110 · 2019-11-01
UNKNOWNHOrmone Therapy Immediately After Histological Diagnosis of Breast CancerNCT03111615 · 2018-05-01
UNKNOWNPAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionNCT03079011 · 2017-03-22
COMPLETEDEndocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryNCT02760030 · 2017-02-16
COMPLETEDSFX-01 in the Treatment and Evaluation of Metastatic Breast CancerNCT02970682 · 2016-10-01
COMPLETEDAdjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenNCT02914158 · 2016-03-30
UNKNOWNMaintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsNCT02511639 · 2014-07-30
COMPLETEDDovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerNCT01484041 · 2012-04-01
TERMINATEDImpact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast CancerNCT01298362 · 2011-03-01
COMPLETEDTrial of Perioperative Endocrine Therapy - Individualising CareNCT02338310 · 2008-09-01
ACTIVE_NOT_RECRUITINGOvercoming Endocrine Resistance in Metastatic Breast CancerNCT02394496 · 2007-11-01
UNKNOWNCommon conditions
Breast Cancer6Metastatic Breast Cancer4Breast Cancer Female2Breast Cancer Metastatic2Hormone Receptor Positive Tumor2Advanced Breast Cancer1Breast Diseases1Breast Neoplasm1Early-stage Breast Cancer1Estrogen Receptor and/or Progesterone Receptor Positive1HER2-positive Breast Cancer1HER2/Neu Negative1Hormone Dependent Neoplasms1Hormone Receptor Positive Breast Carcinoma1Hormone Receptor Positive Malignant Neoplasm of Breast1HR+/HER2- Early Breast Cancer1HR+/HER2+ Early Breast Cancer1Hypoactive Sexual Desire Disorder1Locally Advanced Breast Cancer1Other Disorders of Bone Density and Structure1Stage IA Breast Cancer1Stage IB Breast Cancer1Stage IIA Breast Cancer1Stage IIB Breast Cancer1Stage IIIA Breast Cancer1
Leading sponsors
Second Affiliated Hospital, Zhejiang University, School of Medicine2Centro Hospitalar Lisboa Ocidental1Consorzio Oncotech1Duke University1Evgen Pharma1First Affiliated Hospital, Sun Yat-Sen University1Fuzhou General Hospital1Georgetown University1Hellenic Breast Surgeons Society1Institute of Cancer Research, United Kingdom1Istituto Oncologico Veneto IRCCS1MedSIR1Ohio State University Comprehensive Cancer Center1UNICANCER1University of Illinois at Chicago1
Trial status mix
COMPLETED7
UNKNOWN4
RECRUITING2
TERMINATED2
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
Phase mix
PHASE210
PHASE35
PHASE12
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.